Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas

Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas

Abstract CD19 CAR-T cell therapy shows striking results in treating B cell malignancies. However, approximately two-thirds of the lymphoma patients eventually relapse, with about one-third displaying CD19-negative tumors at relapse. Our previous study showed that CAR-T cells armed with the Helicobac...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Ma, Tina Sarén, Chuan Jin, Hyeong Su Kim, Paola Donaji Contreras Pineda, Marina de Bernard, Rose-Marie Amini, Veronica Rondahl, Gunilla Enblad, Di Yu, Magnus Essand
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
CD20
Chimeric antigen receptor
CAR-T cell
Neutrophil-activating protein
Safety
Toxicity
Online Access:https://doi.org/10.1007/s00262-025-04112-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04112-1

Similar Items